{"id":4658,"date":"2025-10-08T09:41:28","date_gmt":"2025-10-08T09:41:28","guid":{"rendered":"https:\/\/neoplas-med.eu\/en\/?p=4658"},"modified":"2025-10-08T09:44:44","modified_gmt":"2025-10-08T09:44:44","slug":"consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy","status":"publish","type":"post","link":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/","title":{"rendered":"Consortium withdraws from G-BA trial study on cold plasma therapy"},"content":{"rendered":"

Greifswald\/Berlin, September 30, 2025.<\/strong><\/em> The consortium of the three leading cold plasma therapy companies neoplas med GmbH (Greifswald), terraplasma medical GmbH (Munich) and Cinogy GmbH (Duderstadt) will not participate in the clinical trial \u201cCold Plasma Treatment for Chronic Wounds\u201d (ER-21-002), initiated by the Federal Joint Committee (G-BA).<\/strong><\/p>\n

In September 2023, neoplas med GmbH, terraplasma medical GmbH, and Cinogy GmbH formed a consortium to conduct the G-BA trial. The consortium\u2019s goal was to carry out the study under the scientific leadership of Professor Dr. Dr. Hans-Robert Metelmann (Chairman of the Board of the National Center for Plasma Medicine) and thereby establish the scientific and statistical basis for a G-BA benefit assessment.<\/p>\n

The decision to withdraw was not taken lightly. The determining factor was the study framework, which does not ensure implementation of the agreed study protocol in its intended form. In particular, certain providers relevant to real-world care have been excluded from participation and the remuneration for providers set under the uniform value scale is, in the consortium\u2019s view, insufficient to cover their actual effort.<\/p>\n

\u201cWe share the G-BA\u2019s assessment that cold plasma therapy has strong potential and we remain committed to generating additional evidence-based data through appropriate studies,\u201d said Ulrike Sailer, Managing Director of neoplas med GmbH.<\/p>\n

This view was echoed by Jens Kirsch, Managing Director of terraplasma medical GmbH and Benedikt Busse, Managing Director of Cinogy GmbH: \u201eOur goal remains to improve care for patients with chronic wounds. However, under the current conditions, this goal cannot be achieved within the framework of the G-BA trial.\u201d<\/p>\n

\u201cWe would like to thank all partners who have constructively contributed to the process over the past months and hope to continue the dialogue at a later stage,\u201d added Ulrike Sailer. The consortium partners are currently planning their own studies that will reflect all relevant forms of care and create a solid data basis for future assessment procedures.<\/p>\n

About the Consortium<\/strong><\/p>\n

For many years, neoplas med GmbH, terraplasma medical GmbH, and Cinogy GmbH have been developing innovative solutions for the treatment of chronic wounds using physical cold plasma. With their technologies, they contribute to enhanced patient safety, improved quality of life and healthcare innovation in the German healthcare system.<\/p>\n

Press Contact<\/strong><\/p>\n

Michael Behrens
\nPhone: +49 173 3473934
\nEmail: michael.behrens@die-himmelsschreiber.com<\/p>\n

Die HimmelsSchreiber GmbH
\nPhone: +49 30 \/ 3759231-0<\/p>\n","protected":false},"excerpt":{"rendered":"

Greifswald\/Berlin, September 30, 2025. The consortium of the three leading cold plasma therapy companies neoplas med GmbH (Greifswald), terraplasma medical GmbH (Munich) and Cinogy GmbH (Duderstadt) will not participate in the clinical trial \u201cCold Plasma Treatment for Chronic Wounds\u201d (ER-21-002), initiated by the Federal Joint Committee (G-BA). In September 2023, neoplas med GmbH, terraplasma medical … <\/p>\n

Continue reading “Consortium withdraws from G-BA trial study on cold plasma therapy”<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,11],"tags":[],"class_list":["post-4658","post","type-post","status-publish","format-standard","hentry","category-newsticker","category-press-release"],"acf":[],"yoast_head":"\nConsortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH\" \/>\n<meta property=\"og:description\" content=\"Greifswald\/Berlin, September 30, 2025. The consortium of the three leading cold plasma therapy companies neoplas med GmbH (Greifswald), terraplasma medical GmbH (Munich) and Cinogy GmbH (Duderstadt) will not participate in the clinical trial \u201cCold Plasma Treatment for Chronic Wounds\u201d (ER-21-002), initiated by the Federal Joint Committee (G-BA). In September 2023, neoplas med GmbH, terraplasma medical … Continue reading "Consortium withdraws from G-BA trial study on cold plasma therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"neoplas med GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-08T09:41:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-08T09:44:44+00:00\" \/>\n<meta name=\"author\" content=\"kjurke\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kjurke\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/\"},\"author\":{\"name\":\"kjurke\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/person\\\/e8b95ac434ef035faeed506d5c095277\"},\"headline\":\"Consortium withdraws from G-BA trial study on cold plasma therapy\",\"datePublished\":\"2025-10-08T09:41:28+00:00\",\"dateModified\":\"2025-10-08T09:44:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/\"},\"wordCount\":392,\"publisher\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\"},\"articleSection\":[\"newsticker\",\"Press Release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/\",\"name\":\"Consortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#website\"},\"datePublished\":\"2025-10-08T09:41:28+00:00\",\"dateModified\":\"2025-10-08T09:44:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consortium withdraws from G-BA trial study on cold plasma therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\",\"name\":\"neoplas med GmbH\",\"description\":\"Die neoplas med GmbH entwickelt Medizintechnik f\u00fcr den Einsatz physikalischen Kaltplasmas f\u00fcr mehr Lebensqualit\u00e4t.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#organization\",\"name\":\"neoplas med GmbH\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/12\\\/cropped-logoNuMed.png\",\"contentUrl\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/12\\\/cropped-logoNuMed.png\",\"width\":588,\"height\":250,\"caption\":\"neoplas med GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/#\\\/schema\\\/person\\\/e8b95ac434ef035faeed506d5c095277\",\"name\":\"kjurke\",\"url\":\"https:\\\/\\\/neoplas-med.eu\\\/en\\\/news\\\/author\\\/kjurke\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Consortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Consortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH","og_description":"Greifswald\/Berlin, September 30, 2025. The consortium of the three leading cold plasma therapy companies neoplas med GmbH (Greifswald), terraplasma medical GmbH (Munich) and Cinogy GmbH (Duderstadt) will not participate in the clinical trial \u201cCold Plasma Treatment for Chronic Wounds\u201d (ER-21-002), initiated by the Federal Joint Committee (G-BA). In September 2023, neoplas med GmbH, terraplasma medical … Continue reading \"Consortium withdraws from G-BA trial study on cold plasma therapy\"","og_url":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/","og_site_name":"neoplas med GmbH","article_published_time":"2025-10-08T09:41:28+00:00","article_modified_time":"2025-10-08T09:44:44+00:00","author":"kjurke","twitter_card":"summary_large_image","twitter_misc":{"Written by":"kjurke","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/#article","isPartOf":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/"},"author":{"name":"kjurke","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/person\/e8b95ac434ef035faeed506d5c095277"},"headline":"Consortium withdraws from G-BA trial study on cold plasma therapy","datePublished":"2025-10-08T09:41:28+00:00","dateModified":"2025-10-08T09:44:44+00:00","mainEntityOfPage":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/"},"wordCount":392,"publisher":{"@id":"https:\/\/neoplas-med.eu\/en\/#organization"},"articleSection":["newsticker","Press Release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/","url":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/","name":"Consortium withdraws from G-BA trial study on cold plasma therapy - neoplas med GmbH","isPartOf":{"@id":"https:\/\/neoplas-med.eu\/en\/#website"},"datePublished":"2025-10-08T09:41:28+00:00","dateModified":"2025-10-08T09:44:44+00:00","breadcrumb":{"@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neoplas-med.eu\/en\/news\/consortium-withdraws-from-g-ba-trial-study-on-cold-plasma-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoplas-med.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Consortium withdraws from G-BA trial study on cold plasma therapy"}]},{"@type":"WebSite","@id":"https:\/\/neoplas-med.eu\/en\/#website","url":"https:\/\/neoplas-med.eu\/en\/","name":"neoplas med GmbH","description":"Die neoplas med GmbH entwickelt Medizintechnik f\u00fcr den Einsatz physikalischen Kaltplasmas f\u00fcr mehr Lebensqualit\u00e4t.","publisher":{"@id":"https:\/\/neoplas-med.eu\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoplas-med.eu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/neoplas-med.eu\/en\/#organization","name":"neoplas med GmbH","url":"https:\/\/neoplas-med.eu\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2021\/12\/cropped-logoNuMed.png","contentUrl":"https:\/\/neoplas-med.eu\/en\/wp-content\/uploads\/sites\/2\/2021\/12\/cropped-logoNuMed.png","width":588,"height":250,"caption":"neoplas med GmbH"},"image":{"@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/neoplas-med.eu\/en\/#\/schema\/person\/e8b95ac434ef035faeed506d5c095277","name":"kjurke","url":"https:\/\/neoplas-med.eu\/en\/news\/author\/kjurke\/"}]}},"_links":{"self":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/comments?post=4658"}],"version-history":[{"count":2,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4658\/revisions"}],"predecessor-version":[{"id":4661,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/posts\/4658\/revisions\/4661"}],"wp:attachment":[{"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/media?parent=4658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/categories?post=4658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoplas-med.eu\/en\/wp-json\/wp\/v2\/tags?post=4658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}